Kimberly Smith

发表

Improving adherence to antiretroviral therapy.

R. Remien, E. Daar, C. Cohen, 2003, The AIDS reader.

Postmarketing Surveillance of Pregnancy Outcomes With Dolutegravir Use

Kimberly Smith, Melissa Crawford, J. V. van Wyk, 2019, Journal of acquired immune deficiency syndromes.

Racial/ethnic disparities in engagement in care and viral suppression in a large urban HIV clinic.

O. Adeyemi, Kimberly Smith, A. French, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Integrase Inhibitor-Based Antiretroviral Therapy Among Women Living with HIV: Data from the OPERA Cohort.

Kimberly Smith, M. Aboud, V. Vannappagari, 2019, Current HIV research.

CCR5 and CXCR4 expression after highly active antiretroviral therapy (HAART).

H. Kessler, A. Landay, Kimberly Smith, 2002, Journal of acquired immune deficiency syndromes.

Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study

W. K. Henry, D. Podzamczer, H. Stellbrink, 2021, Open forum infectious diseases.

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

S. Swindells, C. Orrell, Kimberly Smith, 2020, The Lancet.

Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials

S. Swindells, S. Oka, C. Orkin, 2020, Journal of acquired immune deficiency syndromes.

Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment

S. Swindells, Kimberly Smith, H. Crauwels, 2021, AIDS (London, England).

Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)

S. Swindells, Kimberly Smith, E. Overton, 2021, The Patient - Patient-Centered Outcomes Research.

Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial.

Kimberly Smith, M. Aboud, R. Kaplan, 2019, The Lancet. Infectious diseases.

Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy – naive adults with HIV-1 infection

J. Rockstroh, P. Cahn, A. Antinori, 2021, AIDS.

Addressing disparities in HIV mortality: antiretroviral therapy is necessary but not sufficient.

Kimberly Smith, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202.

P. Sax, E. Daar, A. Collier, 2014, The Journal of antimicrobial chemotherapy.

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment

D. Fine, Kimberly Smith, N. Bellos, 2009, AIDS.

Optimizing care for African-American HIV-positive patients.

Kimberly Smith, W. Jordan, J. Gathe, 2003, AIDS patient care and STDs.

Virologic failure among people living with HIV initiating dolutegravir-based versus other recommended regimens in real-world clinical care settings.

Richard D Moore, C. Johannes, M. Mugavero, 2017, Journal of acquired immune deficiency syndromes.

Community-associated methicillin-resistant Staphylococcus aureus colonization in high-risk groups of HIV-infected patients.

R. Weinstein, B. Hota, K. Beavis, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

HIV/AIDS Annual Update 2009

K. Obholz, Kimberly Smith, J. Eron, 2009 .

Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitors

M. Lederman, D. Haas, T. Hulgan, 2009, European Journal of Clinical Pharmacology.

HIV risk perception and preexposure prophylaxis interest among a heterosexual population visiting a sexually transmitted infection clinic.

T. Khawcharoenporn, Kimberly Smith, S. Kendrick, 2012, AIDS patient care and STDs.

Superior Efficacy of Dolutegravir (DTG) Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared with lopinavir/ritonavir (LPV/r) Plus 2 NRTIs in Second-Line Treatment — 48-week Data from the DAWNING Study

J. Gatell, Kimberly Smith, M. Aboud, 2019, Journal of Infection and Public Health.

Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.

S. Walmsley, C. Orrell, Kimberly Smith, 2017, The lancet. HIV.

Regional Variation in HIV Clinical Trials Participation in the United States

S. Cohn, Kimberly Smith, M. Cespedes, 2015, Southern medical journal.

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.

T. Holtz, C. del Rio, E. Daar, 2021, The New England journal of medicine.

T cell receptor excision circle (TREC) content following maximum HIV suppression is equivalent in HIV-infected and HIV-uninfected individuals

A. Landay, Kimberly Smith, S. Shott, 2001, AIDS.

A pilot study of the safety and efficacy of cholestin in treating HIV-related dyslipidemia.

H. Kessler, B. Swanson, Kimberly Smith, 2002, Nutrition.

No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV‐1–Infected Subjects

J. Marshall, P. Chan, S. Nepal, 2018, Journal of clinical pharmacology.

Postmarketing Surveillance of Pregnancy Outcomes With Dolutegravir Use

Kimberly Smith, Melissa Crawford, M. Aboud, 2019, Journal of acquired immune deficiency syndromes.

Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.

H. Stellbrink, C. Orkin, Kimberly Smith, 2021, The lancet. HIV.

Long-term changes in circulating CD4 T lymphocytes in virologically suppressed patients after 6 years of highly active antiretroviral therapy

M. Lederman, D. Kuritzkes, R. Bosch, 2004, AIDS.

Classic pyomyositis of the extremities as an unusual manifestation of Blastomyces dermatitidis: a report of two cases

Michael Y. Lin, H. Kessler, Kimberly Smith, 2009, Mycoses.

Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353

P. Sax, D. Haas, E. Acosta, 2019, The Journal of antimicrobial chemotherapy.

Comparable viral decay with initial dolutegravir plus lamivudine versus dolutegravir-based triple therapy.

B. Taiwo, B. Berzins, Kimberly Smith, 2019, The Journal of antimicrobial chemotherapy.

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

B. Gazzard, K. Tashima, M. Shields, 2019, The Lancet.

ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)–infected Participants With HIV-1 RNA <500000 Copies/mL

P. Sax, D. Haas, E. Acosta, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

D. Podzamczer, B. Clotet, H. Stellbrink, 2017, The Lancet.

Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.

J. Gallant, R. Grant, I. Frank, 2017, The lancet. HIV.

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.

J. Eron, Kimberly Smith, W. Spreen, 2015, The Lancet. Infectious diseases.

Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen

M. Lederman, D. Kuritzkes, H. Kessler, 2000, AIDS.

Antiretroviral Therapy and Communities of Color

Kimberly Smith, R. Campo, 2009 .

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.

P. Cahn, S. Swindells, J. Mrus, 2020, The New England journal of medicine.

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.

S. Oka, S. Walmsley, C. Orkin, 2020, The New England journal of medicine.

Selected metabolic and morphologic complications associated with highly active antiretroviral therapy.

Kimberly Smith, 2002, The Journal of infectious diseases.

infection: 48-week results of ALERT

M. Fischl, Kimberly Smith, E. Dejesus, 2008 .

Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial

S. Delany-Moretlwe, J. Hughes, B. G. Mirembe, 2022, The Lancet.

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.

Kimberly Smith, H. Crauwels, E. Overton, 2021, The lancet. HIV.

Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants

G. Wilding, P. Sax, E. Daar, 2017, Therapeutic drug monitoring.

Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients.

M. Fischl, Kimberly Smith, E. Dejesus, 2010, AIDS research and human retroviruses.

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study

J. Routy, S. De Wit, Kimberly Smith, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Treatment with recombinant growth hormone is associated with modest improvement in CD4 lymphocyte reconstitution in HIV-infected persons on antiretroviral therapy: results of ACTG A5174.

M. Saag, R. Bosch, D. Margolis, 2010, AIDS research and human retroviruses.

Challenges and successes in linking HIV-infected women to care in the United States.

Kimberly Smith, M. Aziz, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Minorities Remain Underrepresented in HIV/AIDS Research Despite Access to Clinical Trials

S. Cohn, Kimberly Smith, D. Mildvan, 2014, HIV clinical trials.

Limited immune restoration after 3 years’ suppression of HIV-1 replication in patients with moderately advanced disease

Ryung S. Kim, M. Lederman, D. Kuritzkes, 2002, AIDS.

Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study

Keith Nangle, Kimberly Smith, M. Aboud, 2021, Antimicrobial agents and chemotherapy.

Treating Women with HIV: Is it Different than Treating Men?

Kimberly Smith, M. Aziz, 2012, Current HIV/AIDS Reports.

Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis.

R. Haubrich, G. Robbins, C. Flexner, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Assessing darunavir/ritonavir-based therapy in a racially diverse population: 48-week outcomes from GRACE.

K. Squires, J. Currier, J. Mrus, 2012, Journal of the National Medical Association.

Feasibility of HIV Universal Voluntary Counseling and Testing in a Thai General Practice Clinic

A. Apisarnthanarak, T. Khawcharoenporn, Kimberly Smith, 2016, Journal of the International Association of Providers of AIDS Care.

Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.

D. Podzamczer, C. Orkin, Kimberly Smith, 2019, The lancet. HIV.

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials

J. Rockstroh, P. Cahn, A. Antinori, 2019, Journal of acquired immune deficiency syndromes.

Initial viral load decline and response rates by baseline viral load strata with dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled results from the GEMINI studies

C. Hung, J. Slim, J. Eron, 2019, Journal of Infection and Public Health.

Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy.

P. Sax, B. Taiwo, B. Ha, 2020, AIDS research and human retroviruses.

Seroprevalence study using oral rapid HIV testing in a large urban emergency department.

H. Kessler, Kimberly Smith, D. Rumoro, 2012, The Journal of emergency medicine.

Strategies for initiating combination antiretroviral therapy.

E. Daar, Kimberly Smith, M. Tapper, 2005, AIDS patient care and STDs.

Role of Baseline pol Genotype in HIV-1 Fitness Evolution.

M. Lederman, D. Kuritzkes, G. Vanham, 2003, Journal of acquired immune deficiency syndromes.

Attitudes and perceptions of AIDS clinical trials group site coordinators on HIV clinical trial recruitment and retention: a descriptive study.

M. Fischl, W. King, J. Mitty, 2007, AIDS patient care and STDs.

African Americans and HIV Clinical Research

W. King, Kimberly Smith, 2009 .

2842. Durable Efficacy of Two-Drug Regimen (2DR) of Dolutegravir (DTG) plus Lamivudine (3TC) in Antiretroviral Treatment-Naïve Adults with HIV-1 Infection at 96 Weeks: Subgroup Analyses in the GEMINI Studies

Kimberly Smith, B. Wynne, A. Tenorio, 2019, Open Forum Infectious Diseases.

Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine.

D. Katzenstein, P. Sax, E. Daar, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine

J. van Lunzen, Ping Wang, M. Krystal, 2022, Antimicrobial agents and chemotherapy.

Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.

S. Oka, C. Orkin, Kimberly Smith, 2021, The lancet. HIV.

Paying the price for late starts and early stops: racial and sex disparities in HIV-related mortality.

Kimberly Smith, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Electron beam computed tomography for assessment of coronary artery disease in HIV-infected men receiving antiretroviral therapy.

R. Talwani, S. Rich, H. Kessler, 2002, Journal of acquired immune deficiency syndromes.

HIV-1–Infected Antiretroviral-Treated Patients With Prolonged Partial Viral Suppression: Clinical, Virologic, and Immunologic Course

D. Kuritzkes, H. Kessler, J. Bremer, 2003, Journal of Acquired Immune Deficiency Syndromes.

Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis.

C. Hung, J. Slim, J. Eron, 2020, Journal of acquired immune deficiency syndromes.

Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202

P. Sax, E. Daar, A. Collier, 2019, Antimicrobial Agents and Chemotherapy.

Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and -2 Randomized Clinical Trials.

C. Orkin, Kimberly Smith, B. Wynne, 2020, Journal of acquired immune deficiency syndromes.

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study

S. Swindells, Kimberly Smith, H. Crauwels, 2023, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) Fixed-Dose Combination (FDC) Compared With Ritonavir-Boosted Atazanavir (ATV/r) Plus Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in Treatment-Naive Women With Human Immunodeficiency Virus (HIV)-1 Infection (ARIA Study): Analyses by

Kimberly Smith, M. Aboud, B. Wynne, 2016 .

Protease Inhibitor-Sparing Regimens

Kimberly Smith, 2002, Journal of the International Association of Physicians in AIDS Care.

Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority t

S. Oka, S. Walmsley, G. di Perri, 2023, The lancet. HIV.

HIV/AIDS in U.S. communities of color.

V. Stone, Kimberly Smith, B. Ojikutu, 2009 .